108 related articles for article (PubMed ID: 16555997)
21. Enzyme-catalyzed activation of anticancer prodrugs.
Rooseboom M; Commandeur JN; Vermeulen NP
Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
[TBL] [Abstract][Full Text] [Related]
22. Cytochrome P450 1B1, a novel chemopreventive target for benzo[a]pyrene-initiated human esophageal cancer.
Wen X; Walle T
Cancer Lett; 2007 Feb; 246(1-2):109-14. PubMed ID: 16530937
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover).
Roberts DW; Doerge DR; Churchwell MI; Gamboa da Costa G; Marques MM; Tolleson WH
J Agric Food Chem; 2004 Oct; 52(21):6623-32. PubMed ID: 15479032
[TBL] [Abstract][Full Text] [Related]
24. Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1.
Dawling S; Roodi N; Parl FF
Cancer Res; 2003 Jun; 63(12):3127-32. PubMed ID: 12810639
[TBL] [Abstract][Full Text] [Related]
25. Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment.
D'Uva G; Baci D; Albini A; Noonan DM
Cancer Treat Rev; 2018 Feb; 63():1-18. PubMed ID: 29197745
[TBL] [Abstract][Full Text] [Related]
26. Cytochrome P450 enzymes: novel options for cancer therapeutics.
McFadyen MC; Melvin WT; Murray GI
Mol Cancer Ther; 2004 Mar; 3(3):363-71. PubMed ID: 15026557
[TBL] [Abstract][Full Text] [Related]
27. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis.
Chun YJ; Kim S; Kim D; Lee SK; Guengerich FP
Cancer Res; 2001 Nov; 61(22):8164-70. PubMed ID: 11719446
[TBL] [Abstract][Full Text] [Related]
28. Regulation of cytochrome P-450 (CYP) 1B1 in mouse Hepa-1 variant cell lines: A possible role for aryl hydrocarbon receptor nuclear translocator (ARNT) as a suppressor of CYP1B1 gene expression.
Eltom SE; Zhang L; Jefcoate CR
Mol Pharmacol; 1999 Mar; 55(3):594-604. PubMed ID: 10051545
[TBL] [Abstract][Full Text] [Related]
29. Telomeres and telomerase as targets for anticancer drug development.
Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
[TBL] [Abstract][Full Text] [Related]
30. Tumor-specific expression of cytochrome P450 CYP1B1.
Murray GI; Taylor MC; McFadyen MC; McKay JA; Greenlee WF; Burke MD; Melvin WT
Cancer Res; 1997 Jul; 57(14):3026-31. PubMed ID: 9230218
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA regulates the expression of human cytochrome P450 1B1.
Tsuchiya Y; Nakajima M; Takagi S; Taniya T; Yokoi T
Cancer Res; 2006 Sep; 66(18):9090-8. PubMed ID: 16982751
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human cytochrome CYP 1 enzymes by flavonoids of St. John's wort.
Chaudhary A; Willett KL
Toxicology; 2006 Jan; 217(2-3):194-205. PubMed ID: 16271822
[TBL] [Abstract][Full Text] [Related]
33. Design and Synthesis of New α-Naphthoflavones as Cytochrome P450 (CYP) 1B1 Inhibitors To Overcome Docetaxel-Resistance Associated with CYP1B1 Overexpression.
Cui J; Meng Q; Zhang X; Cui Q; Zhou W; Li S
J Med Chem; 2015 Apr; 58(8):3534-47. PubMed ID: 25799264
[TBL] [Abstract][Full Text] [Related]
34. Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1.
Chang TK; Lee WB; Ko HH
Can J Physiol Pharmacol; 2000 Nov; 78(11):874-81. PubMed ID: 11100935
[TBL] [Abstract][Full Text] [Related]
35. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1.
Luby TM; Cole G; Baker L; Kornher JS; Ramstedt U; Hedley ML
Clin Immunol; 2004 Jul; 112(1):45-53. PubMed ID: 15207781
[TBL] [Abstract][Full Text] [Related]
36. Roles of NADPH-P450 reductase in the O-deethylation of 7-ethoxycoumarin by recombinant human cytochrome P450 1B1 variants in Escherichia coli.
Shimada T; Tsumura F; Gillam EM; Guengerich FP; Inoue K
Protein Expr Purif; 2000 Oct; 20(1):73-80. PubMed ID: 11035953
[TBL] [Abstract][Full Text] [Related]
37. Challenges of cancer drug design: a drug metabolism perspective.
Sanchez RI; Mesia-Vela S; Kauffman FC
Curr Cancer Drug Targets; 2001 May; 1(1):1-32. PubMed ID: 12188889
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 1B1 Overexpression in Cervical Cancers: Cross-sectional Study.
Alshammari FOFO; Al-Saraireh YM; Youssef AMM; Al-Sarayra YM; Alrawashdeh HM
Interact J Med Res; 2021 Oct; 10(4):e31150. PubMed ID: 34636736
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 2W1 (CYP2W1) - ready for use as the biomarker and drug target for cancer?
Pan Y; Ong EC
Xenobiotica; 2017 Oct; 47(10):923-932. PubMed ID: 27690753
[TBL] [Abstract][Full Text] [Related]
40. Highlights of the Second International Symposium on Genetic Anticancer Agents.
Gerritsen WR; Krul MR
Cancer Gene Ther; 2001 Sep; 8(9):678-80. PubMed ID: 11593338
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
